Home > News

News

Starsight Telecast Inc (Rovi) v Virgin Media Ltd [2014] EWHC 8 (pat)9 January 2014Members of Chambers recently appeared for both sides in a partial summary judgment application in the on-going series of litigation between Rovi and Virgin Media. James Abrahams appeared for Rovi defending the application made by Virgin, who were represented by James Whyte. In October 2012 the EPO Opposition Division held the claims of one of […]
(1) Actavis Group PTC EHF (2) Actavis UK Ltd v (1) Sanofi (2) Sanofi Pharma Bristol-Myers Squibb SNC (C-443/12)12 December 2013Four members of chambers recently appeared in a hearing at the CJEU in the much anticipated preliminary reference hearing regarding the availability of Supplementary Protection Certificates (“SPC”). Richard Meade QCand Isabel Jamal appeared for Actavis. Daniel Alexander QC represented Sanofi and Charlotte May was instructed by the United Kingdom Government as an interested party. Sanofi’s […]
HTC Corp v Nokia Corp [2013] EWHC 324712 December 2013Michael Tappin QC  recently appeared with Nicholas Saunders and Miles Copeland for Nokia, the successful patentee in a revocation and infringement action. Nokia’s patent was for a modulator structure using a Gilbert cell in mobile telecommunications. HTC claimed that the patent was invalid for reasons of lack of novelty and for obviousness over two prior […]
Microsoft Corp v Motorola Mobility LLC [2013] EWCA Civ 161311 December 2013Richard Meade QCand James Abrahams recently appeared for Microsoft, the successful respondents to an appeal brought by Motorola, represented by Daniel Alexander QC and Tim Powell. Motorola’s appeal was from the judgment of Arnold J [2012] EWHC 3677 (pat) revoking its European patent relating to the status synchronisation of multiple mobile devices, and dismissing its […]
(1) Hospira UK Ltd (2) Generics (UK) Ltd (t/a Mylan) v Novartis AG [2013] EWCA Civ 166311 December 2013Michael Tappin QC  recently appeared with Tom Mitcheson for Hospira and Generics, the successful respondents to an appeal brought by Novartis against the invalidation of one of its patents. Novartis’ patent related to the use of a particular member of the bisphosphonate class of drugs, zoledronate. Claim 7 claimed the use of zoledronate for the […]